Novartis India to buy Pfizer's Minipress for ₹1,250 crore
Novartis India to buy Pfizer's Minipress for ₹1,250 crore. The acquisition includes trademarks and rights to Minipress, a hypertension drug. This strategic move strengthens Novartis India's portfolio in cardiovascular therapies. The deal value of ₹1,250 crore marks one of the larger pharma asset purchases in India recently.
📊 STOCKS: $NOVARTISIND | 🏢 SECTOR: Pharma | #HIGHIMPACT #Acquisition
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.